Viatris is a global healthcare company formed through the merger of Mylan and Upjohn, a division of Pfizer. It focuses on providing access to medicines, including generic and specialty pharmaceuticals. Major business segments include established brands, generics, and over-the-counter products. The company's primary revenue sources are from prescription medications and a diverse portfolio of therapeutic areas, including infectious diseases, oncology, and cardiovascular health.
Viatris presents a neutral investment profile, appealing to both dividend and value investors due to its consistent dividend yield and established market presence. The stock's performance indicates moderate growth potential, while its current valuation suggests it may also attract value-focused investors. The investment horizon is more suitable for medium to long-term strategies, given the company's stability and market position.
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-11 05:28 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-26 03:37 | Vendi | Mantieni | Weak fundamentals offset by stable dividend yield. |
| 2026-05-18 04:34 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-19 09:18 | Barclays | Target alzato | 17 → 22 | 16.5 |
| 2026-05-08 13:28 | Truist Financial | Target alzato | 18 → 20 | 16.945 |
| 2026-02-09 10:05 | UBS | Rating migliorato | — → 18 | 14.58 |
